Sign in

Acute myeloid leukaemia: trials that stopped early

Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Withdrawn

    A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

    Reason given in the registry

    “insufficient staff and updates in standard practice have made it difficult to recruit participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Dec 2023.

    Phase
    Phase 1/2
    Run by
    Naoyuki G. Saito, M.D., Ph.D.
    Registry record
    NCT05201183
  2. Withdrawn

    Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

    Reason given in the registry

    “Investigator decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Dec 2023.

    Phase
    Phase 1
    Run by
    Juan C. Ramos, MD
    Registry record
    NCT05321940
  3. Suspended

    Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

    Reason given in the registry

    “Pause for changes in development strategies”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Oct 2023.

    Ended
    Dec 2024
    Phase
    Phase 1/2
    Run by
    Innovent Biologics (Suzhou) Co. Ltd.
    Registry record
    NCT04485052
  4. Withdrawn

    Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

    Reason given in the registry

    “study postponed”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Jul 2023.

    Ended
    Sept 2024
    Phase
    Phase 1/2
    Run by
    Actinium Pharmaceuticals
    Registry record
    NCT03932318
  5. Withdrawn

    Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

    Reason given in the registry

    “Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2023.

    Phase
    Phase 1
    Run by
    Amgen
    Registry record
    NCT03904069
  6. Withdrawn

    GM-CLAG in Relapsed/Refractory FLT3-mutated AML

    Reason given in the registry

    “Sponsor withdrew funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Apr 2023.

    Phase
    Phase 1
    Run by
    Ayman H Qasrawi
    Registry record
    NCT05330377
  7. Withdrawn

    Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

    Reason given in the registry

    “Principal investigator decided not to move forward with the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Apr 2023.

    Phase
    Phase 2
    Run by
    Washington University School of Medicine
    Registry record
    NCT04354025
  8. Withdrawn

    Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

    Reason given in the registry

    “The study is not initiated and we want it to be withdrawn.”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Mar 2023.

    Phase
    Phase 1
    Run by
    Shanghai Pudong Hospital
    Registry record
    NCT05513612
  9. Withdrawn

    Diagnosis and Treatment of Periodontal Disease in Patients With AML

    Reason given in the registry

    “PI left institution and research was cancelled due to his departure”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Feb 2023.

    Run by
    Masonic Cancer Center, University of Minnesota
    Registry record
    NCT04530695
  10. Withdrawn

    Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

    Reason given in the registry

    “Change in development plan”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Oct 2022.

    Ended
    Nov 2025
    Phase
    Phase 1/2
    Run by
    Rhizen Pharmaceuticals SA
    Registry record
    NCT05246384
  11. Withdrawn

    CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

    Reason given in the registry

    “Study was split into two new studies before the first participant was enrolled.”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Sept 2022.

    Phase
    Phase 2
    Run by
    Baptist Health South Florida
    Registry record
    NCT04282174
  12. Withdrawn

    A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

    Reason given in the registry

    “Sponsor decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Jun 2022.

    Ended
    Jun 2025
    Phase
    Phase 1/2
    Run by
    Erasca, Inc.
    Registry record
    NCT05279859
  13. Withdrawn

    Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

    Reason given in the registry

    “Drug availability”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jun 2022.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT04655391
  14. Withdrawn

    Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML

    Reason given in the registry

    “Study turned out no longer feasible”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2022.

    Ended
    Dec 2025
    Phase
    Phase 3
    Run by
    University Hospital Heidelberg
    Registry record
    NCT04676243
  15. Withdrawn

    Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

    Reason given in the registry

    “No funding support”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Mar 2022.

    Ended
    Dec 2024
    Phase
    Phase 2
    Run by
    Washington University School of Medicine
    Registry record
    NCT04893915
  16. Withdrawn

    Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

    Reason given in the registry

    “Change of strategy”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Dec 2021.

    Phase
    Phase 1
    Run by
    Aptevo Therapeutics
    Registry record
    NCT04973618
  17. Withdrawn

    HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

    Reason given in the registry

    “Medigene transfered all rights to a new Sponsor”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2021.

    Ended
    Jul 2025
    Phase
    Phase 1
    Run by
    Medigene AG
    Registry record
    NCT04464889

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.